Sort by
Items per page

Send to

Choose Destination

Search results

Items: 42


Relationship of DNA methylation to mutational changes and transcriptional organization in fusion-positive and fusion-negative rhabdomyosarcoma.

Sun W, Chatterjee B, Shern JF, Patidar R, Song Y, Wang Y, Walker RL, Pawel BR, Linardic CM, Houghton P, Hewitt SM, Edelman DC, Khan J, Meltzer PS, Barr FG.

Int J Cancer. 2018 Nov 22. doi: 10.1002/ijc.32006. [Epub ahead of print]


Soft Tissue Sarcoma Cancer Stem Cells: An Overview.

Genadry KC, Pietrobono S, Rota R, Linardic CM.

Front Oncol. 2018 Oct 26;8:475. doi: 10.3389/fonc.2018.00475. eCollection 2018. Review.


Proceedings of the fifth international RASopathies symposium: When development and cancer intersect.

Rauen KA, Schoyer L, Schill L, Stronach B, Albeck J, Andresen BS, Cavé H, Ellis M, Fruchtman SM, Gelb BD, Gibson CC, Gripp K, Hefner E, Huang WYC, Itkin M, Kerr B, Linardic CM, McMahon M, Oberlander B, Perlstein E, Ratner N, Rogers L, Schenck A, Shankar S, Shvartsman S, Stevenson DA, Stites EC, Stork PJS, Sun C, Therrien M, Ullian EM, Widemann BC, Yeh E, Zampino G, Zenker M, Timmer W, McCormick F.

Am J Med Genet A. 2018 Dec;176(12):2924-2929. doi: 10.1002/ajmg.a.40632. Epub 2018 Oct 10.


Loss of MST/Hippo Signaling in a Genetically Engineered Mouse Model of Fusion-Positive Rhabdomyosarcoma Accelerates Tumorigenesis.

Oristian KM, Crose LES, Kuprasertkul N, Bentley RC, Lin YT, Williams N, Kirsch DG, Linardic CM.

Cancer Res. 2018 Oct 1;78(19):5513-5520. doi: 10.1158/0008-5472.CAN-17-3912. Epub 2018 Aug 9.


The Transcriptional Coactivator TAZ Is a Potent Mediator of Alveolar Rhabdomyosarcoma Tumorigenesis.

Deel MD, Slemmons KK, Hinson AR, Genadry KC, Burgess BA, Crose LES, Kuprasertkul N, Oristian KM, Bentley RC, Linardic CM.

Clin Cancer Res. 2018 Jun 1;24(11):2616-2630. doi: 10.1158/1078-0432.CCR-17-1207. Epub 2018 Mar 7.


A Novel Notch-YAP Circuit Drives Stemness and Tumorigenesis in Embryonal Rhabdomyosarcoma.

Slemmons KK, Crose LES, Riedel S, Sushnitha M, Belyea B, Linardic CM.

Mol Cancer Res. 2017 Dec;15(12):1777-1791. doi: 10.1158/1541-7786.MCR-17-0004. Epub 2017 Sep 18.


The NOTCH1/SNAIL1/MEF2C Pathway Regulates Growth and Self-Renewal in Embryonal Rhabdomyosarcoma.

Ignatius MS, Hayes MN, Lobbardi R, Chen EY, McCarthy KM, Sreenivas P, Motala Z, Durbin AD, Molodtsov A, Reeder S, Jin A, Sindiri S, Beleyea BC, Bhere D, Alexander MS, Shah K, Keller C, Linardic CM, Nielsen PG, Malkin D, Khan J, Langenau DM.

Cell Rep. 2017 Jun 13;19(11):2304-2318. doi: 10.1016/j.celrep.2017.05.061.


Role of the YAP Oncoprotein in Priming Ras-Driven Rhabdomyosarcoma.

Slemmons KK, Crose LE, Rudzinski E, Bentley RC, Linardic CM.

PLoS One. 2015 Oct 23;10(10):e0140781. doi: 10.1371/journal.pone.0140781. eCollection 2015.


A Review: Molecular Aberrations within Hippo Signaling in Bone and Soft-Tissue Sarcomas.

Deel MD, Li JJ, Crose LE, Linardic CM.

Front Oncol. 2015 Sep 2;5:190. doi: 10.3389/fonc.2015.00190. eCollection 2015. Review.


Recent Insights into Notch Signaling in Embryonal Rhabdomyosarcoma.

Conti B, Slemmons KK, Rota R, Linardic CM.

Curr Drug Targets. 2016;17(11):1235-44. Review.


Histone Deacetylase Inhibitors Inhibit Rhabdomyosarcoma by Reactive Oxygen Species-Dependent Targeting of Specificity Protein Transcription Factors.

Hedrick E, Crose L, Linardic CM, Safe S.

Mol Cancer Ther. 2015 Sep;14(9):2143-53. doi: 10.1158/1535-7163.MCT-15-0148. Epub 2015 Jul 10.


Secreted Frizzled-Related Protein 3 (SFRP3) Is Required for Tumorigenesis of PAX3-FOXO1-Positive Alveolar Rhabdomyosarcoma.

Kephart JJ, Tiller RG, Crose LE, Slemmons KK, Chen PH, Hinson AR, Bentley RC, Chi JT, Linardic CM.

Clin Cancer Res. 2015 Nov 1;21(21):4868-80. doi: 10.1158/1078-0432.CCR-14-1797. Epub 2015 Jun 12.


Asparaginase-Induced Hypertriglyceridemia Presenting as Pseudohyponatremia during Leukemia Treatment.

Hinson A, Newbern D, Linardic CM.

Case Rep Pediatr. 2014;2014:635740. doi: 10.1155/2014/635740. Epub 2014 Oct 27.


Rhabdomyosarcoma: current challenges and their implications for developing therapies.

Hettmer S, Li Z, Billin AN, Barr FG, Cornelison DD, Ehrlich AR, Guttridge DC, Hayes-Jordan A, Helman LJ, Houghton PJ, Khan J, Langenau DM, Linardic CM, Pal R, Partridge TA, Pavlath GK, Rota R, Schäfer BW, Shipley J, Stillman B, Wexler LH, Wagers AJ, Keller C.

Cold Spring Harb Perspect Med. 2014 Nov 3;4(11):a025650. doi: 10.1101/cshperspect.a025650. Review.


Alveolar rhabdomyosarcoma-associated PAX3-FOXO1 promotes tumorigenesis via Hippo pathway suppression.

Crose LE, Galindo KA, Kephart JG, Chen C, Fitamant J, Bardeesy N, Bentley RC, Galindo RL, Chi JT, Linardic CM.

J Clin Invest. 2014 Jan;124(1):285-96. doi: 10.1172/JCI67087. Epub 2013 Dec 16.


RAS and ROS in rhabdomyosarcoma.

Zhang M, Linardic CM, Kirsch DG.

Cancer Cell. 2013 Dec 9;24(6):689-91. doi: 10.1016/j.ccr.2013.11.015.


Distinct and overlapping sarcoma subtypes initiated from muscle stem and progenitor cells.

Blum JM, Añó L, Li Z, Van Mater D, Bennett BD, Sachdeva M, Lagutina I, Zhang M, Mito JK, Dodd LG, Cardona DM, Dodd RD, Williams N, Ma Y, Lepper C, Linardic CM, Mukherjee S, Grosveld GC, Fan CM, Kirsch DG.

Cell Rep. 2013 Nov 27;5(4):933-40. doi: 10.1016/j.celrep.2013.10.020. Epub 2013 Nov 14.


Human rhabdomyosarcoma cell lines for rhabdomyosarcoma research: utility and pitfalls.

Hinson AR, Jones R, Crose LE, Belyea BC, Barr FG, Linardic CM.

Front Oncol. 2013 Jul 17;3:183. doi: 10.3389/fonc.2013.00183. eCollection 2013.


FGFR4 blockade exerts distinct antitumorigenic effects in human embryonal versus alveolar rhabdomyosarcoma.

Crose LE, Etheridge KT, Chen C, Belyea B, Talbot LJ, Bentley RC, Linardic CM.

Clin Cancer Res. 2012 Jul 15;18(14):3780-90. doi: 10.1158/1078-0432.CCR-10-3063. Epub 2012 May 30.


In vivo imaging of tumor-propagating cells, regional tumor heterogeneity, and dynamic cell movements in embryonal rhabdomyosarcoma.

Ignatius MS, Chen E, Elpek NM, Fuller AZ, Tenente IM, Clagg R, Liu S, Blackburn JS, Linardic CM, Rosenberg AE, Nielsen PG, Mempel TR, Langenau DM.

Cancer Cell. 2012 May 15;21(5):680-93. doi: 10.1016/j.ccr.2012.03.043.


Embryonic signaling pathways and rhabdomyosarcoma: contributions to cancer development and opportunities for therapeutic targeting.

Belyea B, Kephart JG, Blum J, Kirsch DG, Linardic CM.

Sarcoma. 2012;2012:406239. doi: 10.1155/2012/406239. Epub 2012 Apr 30.


Recurrent inflammatory myofibroblastic tumor of the heart.

Andersen ND, DiBernardo LR, Linardic CM, Camitta MG, Lodge AJ.

Circulation. 2012 May 15;125(19):2379-81. doi: 10.1161/CIRCULATIONAHA.111.066191. No abstract available.


Inhibition of the Notch-Hey1 axis blocks embryonal rhabdomyosarcoma tumorigenesis.

Belyea BC, Naini S, Bentley RC, Linardic CM.

Clin Cancer Res. 2011 Dec 1;17(23):7324-36. doi: 10.1158/1078-0432.CCR-11-1004. Epub 2011 Sep 23.


Receptor tyrosine kinases as therapeutic targets in rhabdomyosarcoma.

Crose LE, Linardic CM.

Sarcoma. 2011;2011:756982. doi: 10.1155/2011/756982. Epub 2011 Jan 2.


Defining the cooperative genetic changes that temporally drive alveolar rhabdomyosarcoma.

Naini S, Etheridge KT, Adam SJ, Qualman SJ, Bentley RC, Counter CM, Linardic CM.

Cancer Res. 2008 Dec 1;68(23):9583-8. doi: 10.1158/0008-5472.CAN-07-6178.


PAX3-FOXO1 fusion gene in rhabdomyosarcoma.

Linardic CM.

Cancer Lett. 2008 Oct 18;270(1):10-8. doi: 10.1016/j.canlet.2008.03.035. Epub 2008 May 23. Review.


Genetic modeling of Ras-induced human rhabdomyosarcoma.

Linardic CM, Counter CM.

Methods Enzymol. 2008;438:419-27. doi: 10.1016/S0076-6879(07)38028-2.


The PAX3-FKHR fusion gene of rhabdomyosarcoma cooperates with loss of p16INK4A to promote bypass of cellular senescence.

Linardic CM, Naini S, Herndon JE 2nd, Kesserwan C, Qualman SJ, Counter CM.

Cancer Res. 2007 Jul 15;67(14):6691-9.


A network of genetic events sufficient to convert normal human cells to a tumorigenic state.

Kendall SD, Linardic CM, Adam SJ, Counter CM.

Cancer Res. 2005 Nov 1;65(21):9824-8.


Genetic modeling of human rhabdomyosarcoma.

Linardic CM, Downie DL, Qualman S, Bentley RC, Counter CM.

Cancer Res. 2005 Jun 1;65(11):4490-5.


Rescue of an hTERT mutant defective in telomere elongation by fusion with hPot1.

Armbruster BN, Linardic CM, Veldman T, Bansal NP, Downie DL, Counter CM.

Mol Cell Biol. 2004 Apr;24(8):3552-61.


Differential effects of rapamycin on mammalian target of rapamycin signaling functions in mammalian cells.

Edinger AL, Linardic CM, Chiang GG, Thompson CB, Abraham RT.

Cancer Res. 2003 Dec 1;63(23):8451-60.


Characterization of the cytotoxic activities of novel analogues of the antitumor agent, lavendamycin.

Fang Y, Linardic CM, Richardson DA, Cai W, Behforouz M, Abraham RT.

Mol Cancer Ther. 2003 Jun;2(6):517-26.


Myelodysplasia as masquerader: A woman with hypereosinophilic syndrome and twelve years of "chronic ITP".

Linardic CM, Gong JZ, Rosoff PM.

Med Pediatr Oncol. 2002 Aug;39(2):137-8. No abstract available.


Identification of a distinct pool of sphingomyelin involved in the sphingomyelin cycle.

Linardic CM, Hannun YA.

J Biol Chem. 1994 Sep 23;269(38):23530-7.


Sphingolipid breakdown products: anti-proliferative and tumor-suppressor lipids.

Hannun YA, Linardic CM.

Biochim Biophys Acta. 1993 Dec 21;1154(3-4):223-36. Review.


Programmed cell death induced by ceramide.

Obeid LM, Linardic CM, Karolak LA, Hannun YA.

Science. 1993 Mar 19;259(5102):1769-71.


Modulation of cell growth and differentiation by ceramide.

Bielawska A, Linardic CM, Hannun YA.

FEBS Lett. 1992 Jul 28;307(2):211-4.


Brefeldin A promotes hydrolysis of sphingomyelin.

Linardic CM, Jayadev S, Hannun YA.

J Biol Chem. 1992 Jul 25;267(21):14909-11.

Supplemental Content

Loading ...
Support Center